1. Home
  2. TKNO vs MOLN Comparison

TKNO vs MOLN Comparison

Compare TKNO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$4.76

Market Cap

280.9M

Sector

Health Care

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$3.81

Market Cap

143.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TKNO
MOLN
Founded
1996
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.9M
143.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TKNO
MOLN
Price
$4.76
$3.81
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
238.2K
4.4K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
43.86
N/A
EPS
N/A
N/A
Revenue
$40,520,000.00
N/A
Revenue This Year
$8.27
N/A
Revenue Next Year
$13.13
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
7.35
N/A
52 Week Low
$1.91
$3.41
52 Week High
$6.68
$5.36

Technical Indicators

Market Signals
Indicator
TKNO
MOLN
Relative Strength Index (RSI) 54.91 45.38
Support Level $4.09 $3.61
Resistance Level $4.94 $4.01
Average True Range (ATR) 0.47 0.13
MACD -0.01 0.00
Stochastic Oscillator 41.95 31.11

Price Performance

Historical Comparison
TKNO
MOLN

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: